Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme

Oncotarget
Wonyoung KangDo-Hyun Nam

Abstract

Glioblastoma multiforme (GBM) possesses florid angiogenesis. However, the anti-angiogenic agent, Bevacizumab, did not improve overall survival of GBM patients. For more durable anti-angiogenic treatment, we interrogated resistant mechanisms of GBM against Bevacizumab. Serial orthotopic transplantation of in vivo Bevacizumab-treated GBM cells provoked complete refractoriness to the anti-angiogenic treatment. These tumors were also highly enriched with malignant phenotypes such as invasiveness, epithelial to mesenchymal transition, and stem-like features. Through transcriptome analysis, we identified that Talin1 (TLN1) significantly increased in the refractory GBMs. Inhibition of TLN1 not only attenuated malignant characteristics of GBM cells but also reversed the resistance to the Bevacizumab treatment. These data implicate TLN1 as a novel therapeutic target for GBM to overcome resistance to anti-angiogenic therapies.

References

Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold F Dvorak
Aug 2, 2003·Nature Cell Biology·David A Calderwood, Mark H Ginsberg
Jan 6, 2007·Science·Ke HuClare M Waterman-Storer
Jul 24, 2007·Nature Reviews. Neuroscience·Rakesh K JainTracy T Batchelor
May 9, 2008·The New England Journal of Medicine·Gregg L Semenza
Jul 25, 2008·Nature Reviews. Cancer·Gabriele Bergers, Douglas Hanahan
Aug 8, 2008·Expert Reviews in Molecular Medicine·Joshua C AndersonCandece L Gladson
Oct 22, 2008·Expert Review of Neurotherapeutics·Marc C Chamberlain
Oct 22, 2008·Expert Review of Neurotherapeutics·Sajani S Lakka, Jasti S Rao
Jan 31, 2009·Science·Armando del RioMichael P Sheetz
Jun 12, 2009·PloS One·W Shawn CarbonellRuth Muschel
Oct 15, 2009·Nature Reviews. Neurology·Andrew D NordenPatrick Y Wen
Oct 27, 2009·Future Oncology·Enrico FranceschiAlba A Brandes
Feb 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Sarah J ConleyMax S Wicha
May 19, 2012·Expert Review of Anticancer Therapy·Maria Ignez BraghiroliPaulo M Hoff
May 19, 2012·Expert Review of Anticancer Therapy·Mairéad G McNamara, Warren P Mason
Dec 20, 2012·Expert Review of Anticancer Therapy·Olivier L Chinot
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arman JahangiriManish K Aghi
Mar 21, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Yasushi SodaInder M Verma
Oct 18, 2013·The New England Journal of Medicine·Sunit Das, Philip A Marsden
Dec 11, 2013·Expert Opinion on Investigational Drugs·Isabel Arrillaga-RomanyPatrick Y Wen

❮ Previous
Next ❯

Citations

Nov 12, 2016·Neurochemical Research·Jiang Shan ZhanAlbert Cheung Hoi Yu
Jan 14, 2016·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Jianfa JiangYan Deng
Mar 23, 2021·Reproductive Biology and Endocrinology : RB&E·Xian TangJianfa Jiang

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft
Feature Extraction

Software Mentioned

Agilent Feature Extraction
Biocarta
Agilent Genomic Work Bench

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Expert Review of Anticancer Therapy
Mairéad G McNamara, Warren P Mason
Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte
Yasushi SodaInder M Verma
© 2021 Meta ULC. All rights reserved